1. Cell Cycle/DNA Damage PI3K/Akt/mTOR
  2. DNA-PK
  3. DNA-PK-IN-8

DNA-PK-IN-8 (compound DK1) 是一种高效且具有选择性和口服活性的 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂,IC50 为 0.8 nM。DNA-PK-IN-8 与 Doxorubicin 联合使用时,对一系列癌细胞具有协同抗增殖活性,并能显著抑制 HL-60 肿瘤的生长。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

DNA-PK-IN-8 Chemical Structure

DNA-PK-IN-8 Chemical Structure

CAS No. : 2823369-81-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin[1].

IC50 & Target

IC50: 0.8 nM (DNA-PK)[1]

体外研究
(In Vitro)

DNA-PK-IN-8 (compound DK1) decreases the expression levels of γH2A.X in a concentration-dependent manner in HCT-116 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence

Cell Line: HCT-116 (treated with Bleomycin for 6 hours)[1]
Concentration: 1, 5, and 10 μM
Incubation Time: 6 hours
Result: Decreased the expression levels of γH2A.X in a concentration-dependent manner.
体内研究
(In Vivo)

DNA-PK-IN-8 (100 mg/kg; PO; QD for 16 days) significantly suppresses HL-60 tumor growth when co-administrating with Doxorubicin[1].
DNA-PK-IN-8 (5 mg/kg; PO; single dosage) exhibits reasonable pharmacokinetic properties in vitro and in vivo as an oral drug candidate[1].
Pharmacokinetic Parameters of DNA-PK-IN-8 in Sprague-Dawley rats[1].

PO (5 mg/kg)
Tmax (h) 0.42 ± 0.11
t1/2 (h) 1.59 ± 0.26
Cmax (ng/mL) 810 ± 122.32
AUC0-∞ (ng/mL·h) 3598.7 ± 769.81
MRT0-∞ (h) 2.29 ± 0.18

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HL-60 tumor-bearing nude mice model[1]
Dosage: 100 mg/kg
Administration: PO; QD for 16 days
Result: Led to significant tumor-suppressing effects with TGI values of 52.4% and 62.4% for tumor weight and tumor volume, respectively, when co-administrated with Doxorubicin.
Animal Model: Sprague-Dawley rats[1]
Dosage: 5 mg/kg
Administration: PO; single dosage (Pharmacokinetic Analysis)
Result: Exhibited reasonable pharmacokinetic properties in vitro and in vivo as an oral drug candidate.
分子量

394.43

Formula

C19H22N8O2

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献

DNA-PK-IN-8 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
DNA-PK-IN-8
目录号:
HY-146565
需求量: